Suven Life Sciences gets patent for neuro-degenerative molecule

Suven Life Sciences has received one product patent from New Zealand for its molecule to be used in the treatment of neuro-degenerative diseases, reported PTI. With this new patent, Suven has a total of 26 patents from New Zealand. The new patent is valid through 2033, Suven Life Sciences said in a BSE filing. "We are very pleased by the grant of these patents to Suven for our pipeline of

We maintain our Neutral view on Dr Reddy's Laboratories Ltd - Angel Broking

Below is the views on Dr Reddy's Laboratories Ltd By Ms. Sarabjit Kour Nangra (VP Research- Pharma, Angel Broking Pvt Ltd):

“Dr Reddy's Laboratories Ltd and Integra LifeSciences Holdings Corporation, a global medical Technology company, have entered into an exclusive distribution agreement. Under the agreement, will market and distribute

Update On Suven Life Sciences Ltd - SPA Sec

Hyderabad based Suven Life Sciences is a Contract Research and Manufacturing Services (CRAMS) based company with strong focus on drug discovery. Company has four manufacturing plants and three R&D centres. Suven has business relationships with 20+ innovators across the globe. Steady CRAMS business and low debt in spite of cash burning drug discovery research are key positives for Suven. Dur

28/03/2017 2:46:45 PM | Posted in Broking Firm Views - Long Term Report read full news
Hold Divis Laboratories Ltd For Target Rs.600.00 - RCML

Conference call takeaways

DIVI’s management hosted a conference call to address queries on the import alert received from USFDA for its Vizag Unit-2. Management stated that the import alert came as a surprise, and the company was in discussions with consultants to understand the reasons behind the imposition of clause 99-32. Note that post the 48

28/03/2017 2:38:23 PM | Posted in Broking Firm Views - Long Term Report read full news
Dishman Pharma zooms 20% on merger updates

Shares of Dishman Pharmaceuticals rallied 20 per cent and locked in upper circuit on the Bombay Stock Exchange after the company informed about its amalgamation with Carbogen Amcis (India) (CAIL) and Dishman Care (DCL) with effective from March 17.

Following the announcement, shares of company gained as much as 19.99 per cent to hit 52-week high in intra-day to trade at Rs 278.20 apie

Nifty Pharma has immediate support placed at 10050 levels - GEPL

Observation

* NIFTY PHARMA is one of the perennially underperforming sectoral indices, as it closed down by around 1.11% at 10556.35, as against a down move of 0.57% in benchmark NIFTY 50.

* The Sector had made a recent swing high @ 11215.45 in the month of Dec 2016, lower, as compared to Sep 2016. Thus it has failed to sustain at higher leve

27/03/2017 3:20:26 PM | Posted in Broking Firm Views - Sector Report read full news
Buy Glenmark Pharma Ltd For Target Rs.950-970.00 - Reliance Sec

* Glenmark Pharma reversed after taking support of its long-term moving average 200-day SMA and also its intermediate rising trend line.

* Positive cross-over in key technical indicators from their oversold zone is signaling that stock is on verge of turnaround and soon it will resume the uptrend.

* On the higher side, the stock will face hurdles around its

24/03/2017 11:50:11 AM | Posted in Broking Firm Views - Short Term Report read full news
Neutral On Dr. Reddy's Laboratories Ltd For Target Rs.2,875.00 - Motilal Oswal

Duvvada 483 observations out; data integrity issues persist

* Dr Reddy’s Labs (DDRD) has been issued 483 observations (4–5 are repeated) by the US FDA for its Duvvada plant. The FDA investigation has also revealed data integrity issues (e.g., Observation 3, 4). Given that the FDA has maintained a zero tolerance policy toward oncology inject

23/03/2017 2:55:10 PM | Posted in Broking Firm Views - Long Term Report read full news
Neutral On Divi's Laboratories Ltd For Target Rs.600.00 - Motilal Oswal

Regulatory uncertainty to keep stock price range-bound in near term

* US FDA has issued an import alert on DIVI’s Visakhapatnam-based plant, Unit-2. However, it has exempted nine products including Naproxen and Gabapentin from the import alert list. n US FDA had inspected Unit-2 for eight days from November 29 to December 06, 2016, following whic

23/03/2017 2:48:03 PM | Posted in Broking Firm Views - Long Term Report read full news
U.S. bans Divi's factory, shares hit 3-year low

MUMBAI- U.S. health regulators have banned a drug production site in India belonging to Divi's Laboratories Ltd  due to manufacturing violations, sending the company's shares down to a near three-year low on Wednesday.

This comes at a time when an increasingly protectionist stance by U.S. President Donald Trump is threatening to make the operating environ

Divi's Lab extends loss post US FDA alert; scrip hits 52-week low

Shares of Divi's Laboratories continued losing streak of the second day and tanked over 3 per cent, hitting 52-week low, on the Bombay Stock Exchange after the company said that US-FDA has issued an Import Alert 66-40 on the products manufactured at the company's Unit-II at Visakhapatnam, Andhra Pradesh.

Extending previous session losses, shares of company declined as much as

Hold Divis Laboratories Ltd - Sharekhan

Key points

The event:

The US Food & Drug Administration (USFDA) has issued an import alert for Divis Laboratories’ Unit-2 at Visakhapatnam, Andhra Pradesh. The US regulator has exempted ten products of the company from the import alert (Levetiracetam, Gabapentin, Lamotrigine, Capecitabine, Naproxen

22/03/2017 12:30:44 PM | Posted in Broking Firm Views - Long Term Report read full news
Hold Divis Laboratories Ltd For Target Rs.600.00 - RCML

Import alert shocker at Vizag; downgrade to HOLD

The USFDA has issued an import alert at DIVI’s Unit-II Vizag plant, albeit with some product exemptions. While this is better than a full import ban, we worry about the potential cascade of structural issues such as order cancellations, loss of customer confidence and rigorous inspections by other

22/03/2017 12:06:17 PM | Posted in Broking Firm Views - Long Term Report read full news
Dr. Reddy's Lab hits 52-week low on heavy volume

Shares of drug maker Dr. Reddy's Laboratories plunged over 5 per cent, hitting 52-week low, on the Bombay Stock Exchange amid spurt in volume trade after media reports suggested that US FDA found repeat observations from 2015 warning letter. According to ET Now, the company has failed to maintain complete data to ensure compliance.

Even, exchange has sought clarification regarding

Divi's Lab nosedives nearly 20% on US FDA alert

Shares of Divi's Laboratories plunged nearly 20 per cent on the Bombay Stock Exchange after the company said that US-FDA has issued an Import Alert 66-40 on the products manufactured at the company's Unit-II at Visakhapatnam, Andhra Pradesh. Weighed down by the development, shares of company declined as much as 19.69 per cent to hit intra-day low of Rs 635.00 apiece on the Bombay Stock

Buy DIVI'S Laboratories Ltd For Target Rs.855.00 - Religare Sec

Derivative Ideas

DIVISLAB added around 4.5% of open interest as fresh long positions. Daily vwap is around 786.50 levels. On charts, it has witnessed upside breakout from two month long congestion zone with noticeable rise in volumes. We suggest buying DIVISLAB as per levels given below.

 

Strate

21/03/2017 9:53:56 AM | Posted in Broking Firm Views - Short Term Report read full news
Buy Granules India Ltd For Target Rs.145.00 - Religare Sec

Granules India Limited (GRANULES)

GRANULES has registered a fresh buying pivot on the daily chart after consolidating in a narrow range above its multiple moving averages. We advise traders to accumulate fresh in the given range.

21/03/2017 9:47:07 AM | Posted in Broking Firm Views - Short Term Report read full news

Poly Medicure gain on fixing record date for bonus issue

Shares of Poly Medicure surged nearly 7 per cent on the Bombay Stock Exchange after the company fixed March 28, 2017 as record date for the 1:1 bonus issue. The stock will turn ex-bonus on March 24, 2017. “The company has fixed Tuesday the 28th day of March, 2017 as record date for the purpose of ascertaining the eligibility of shareholders who would be entitled to receive 1 (one) new bon

Buy Ajanta Pharma Ltd For Target Rs.1880.00 - Religare Sec

Strategy:-

AJANTPHARM added around 4.5% of open interest as long positions along with some delivery based buying in previous sessions. On charts, stock has created a fresh buying pivot on daily as well as weekly charts. We recommend buying AJANTPHARM as per levels mentioned below.

 

BUY AJANTPHARM MAR FUTS BETWEEN 1775-1785, S

18/03/2017 10:55:57 AM | Posted in Broking Firm Views - Short Term Report read full news
Update On Dr. Reddy's Laboratories Ltd - Motilal Oswal

DR REDDY’S LABORATORIES

Strong cash flow growth, earnings remain subdued

Dr. Reddy’s Laboratories’ (DRRD) FY16 annual report analysis highlights a muted 4% increase in consolidated operating revenue to INR154.7b (FY15: INR148.2b), primarily on account of (a) USFDA warning letter, which has de

17/03/2017 2:24:40 PM | Posted in Broking Firm Views - Long Term Report read full news
Buy Lupin Ltd For Target Rs.1,520.00 - Reliance Sec

*The stock has made a strong bottom in the last few weeks at sub 1400 with strong volumes and positive price action in the last few days.

* The key technical indicators and RSI has also reversed turning upwards and as the stock is in poised for a breakout from current levels.

*The stock has closed near its short term averages confirming the uptrend and the recent swing high

17/03/2017 11:43:38 AM | Posted in Broking Firm Views - Short Term Report read full news
Pharma Sector - High base effect and price revisions take toll on IPM growth - Emkay

High base effect and price revisions take toll on IPM growth

Indian Pharma Market – Monthly checkup

* The Indian Pharmaceutical Market (IPM) reported sub-par growth of c3% YoY to Rs.90.3bn for the month of Feb’17. A high base YoY as well as continuing pricing interventions by the NPPA continue to ensure monthly gr

16/03/2017 3:46:49 PM | Posted in Broking Firm Views - Sector Report read full news
Buy Sun Pharmaceutical Industries Ltd For Target Rs.775.00 - Sharekhan

Key points

* The event:

The US Food and Drug Administration (USFDA) has lifted the Import Alert imposed on Sun Pharmaceutical Industries’ Mohali (Punjab) manufacturing facility, besides removing the facility from the Official Action Initiated (OAI) status. The USFDA had taken action against the company&r

16/03/2017 3:10:00 PM | Posted in Broking Firm Views - Long Term Report read full news